哮喘的生物治疗——波兰过敏症学会(PTA)和波兰肺病学会(PTChP)立场声明

IF 0.2 Q4 ALLERGY

Alergologia Polska - Polish Journal of Allergology Pub Date : 2020-01-01 DOI:10.5114/pja.2020.96664

B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus

{"title":"哮喘的生物治疗——波兰过敏症学会(PTA)和波兰肺病学会(PTChP)立场声明","authors":"B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus","doi":"10.5114/pja.2020.96664","DOIUrl":null,"url":null,"abstract":"Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.96664","citationCount":"1","resultStr":"{\"title\":\"Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)\",\"authors\":\"B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus\",\"doi\":\"10.5114/pja.2020.96664\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5114/pja.2020.96664\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pja.2020.96664\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2020.96664","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

摘要

生物治疗是各种疾病谱系管理的突破，也涉及哮喘治疗，介绍了关于生物制剂在严重哮喘治疗策略中的作用的数据，概述了2型炎症介质如何驱动疾病的病理，给出了批准的生物治疗方案的理由，也强调了针对非2型炎症的治疗策略的发展，以及关于风险和风险的数据讨论了生物制剂的安全性，包括重症哮喘患者对这种可靠有效的治疗方法的分类特点，并对如何在COVID-19流行时期认识生物制剂的安全性提出了展望

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)

Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.